Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05119855 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
NCT05119855 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 165 participants.
The verdict
NCT05119855, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
Study Summary
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.
Interventions
- BIOLOGICAL 9vHPV Vaccine
- BIOLOGICAL mRNA-1273 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2023-12-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05119855
The ClinicalTrials.gov registry entry for NCT05119855 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 9vHPV Vaccine is the first listed.
NCT05119855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05119855 about?
NCT05119855 is a clinical study titled "Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)". The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and gir...
What is the current status of trial NCT05119855?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2022-03-28. Estimated completion is 2023-12-12.
What interventions are being tested in trial NCT05119855?
The interventions under investigation include: 9vHPV Vaccine (BIOLOGICAL), mRNA-1273 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05119855?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.